Oncofactory operates a unique technological platform exploiting an innovative patient-derived xenograft (PDX) animal model, the avian embryo. Miniature replicas of tumors from patient samples (AVI-PDX™) or from cell lines (AVI-cellDX™) are created in a series of embryos, which can receive therapeutic treatments.
Our technology allows modeling the heterogeneity of patient tumors, statistical analysis of treatment efficacies, and a range of molecular analyses for biomarker and therapeutic target discovery.
The AVI-PDX™ model of Oncofactory holds the unique advantage of allowing the creation of tumors and the delivery of therapeutic compounds (small molecule, targeted therapy, immunotherapy) in only a few days. Moreover, the tumorigenesis is targeted onto tissues which are homologous to those in which primary tumors emerge in the patient or in known sites of metastasis. Tumor replicas are imaged in 3D in the entire organism by using high resolution confocal microscopy. A range of molecular analyses can also be conducted on tumor replicas, host tissues and fluids, to achieve a molecular profiling characterizing the sensitivity and resistance to treatments.
Our most recent R&D achievement: iAVI-models to evaluate immunotherapy in mono and combi-therapies
CELL LINES
PATIENT BIOPSIES
CELL LINES
Humanized with immune cells
PATIENT BIOPSIES
Humanized with immune cells
Graft of patient sample into the embryo
KEY ADVANTAGES
